MRK vs VRT: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Vertiv Holdings Co — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-18.
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
VS
Vertiv Holdings Co · Industrials
$307.34
-11.3% upside to fair value
Grade D
High Quality
QuantHub Verdict
MRK has more upside to fair value
(-2.9%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
VRT |
| Current Price |
$121.42 |
$307.34 |
| Fair Value Estimate |
$118.00 |
$272.65 |
| Upside to Fair Value |
-2.9%
|
-11.3%
|
| Market Cap |
$300.2B |
$117.6B |
| Forward P/E |
14.0x
|
88.2x
|
| EV / EBITDA |
11.8x
|
55.3x
|
| Price / Sales |
4.1x
|
11.5x
|
| Price / FCF |
21.4x
|
61.2x
|
| Revenue Growth YoY |
+1.3%
|
+7.6%
|
| Gross Margin |
81.5%
|
34.8%
|
| Operating Margin |
41.2%
|
18.2%
|
| Return on Equity |
34.7%
|
40.3%
|
| Dividend Yield |
3.1% |
0% |
| FCF Yield |
4.7%
|
1.63%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Vertiv Holdings Co operates as a global leader in digital critical infrastructure, providing technology products and solutions primarily for data centers, telecom, and AI-driven markets. The company demonstrates strong business quality with 40.3% return on equity, 7.6% revenue growth, and 11.8% earnings growth year-over-year, supported by a robust $1.89 billion free cash flow and a $15 billion ba…
Accumulation Zones
| Metric |
MRK |
VRT |
| Zone Low |
$88.00 |
$204.49 |
| Zone High |
$100.00 |
$231.75 |
| In Buy Zone? |
No
|
No
|